This inventor holds 5 USPTO granted patents, plus 2 CIPO patents. Top assignees: Asta Medica, Aktiengesellschaft, Arzneimittelwerk Dresden Gmbh. Active years: 1999-2003.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1999-2003
Title: The Innovative Mind of Karl-Friedrich Landgraf
Introduction
Karl-Friedrich Landgraf is a prominent inventor based in Dresden, Germany. With a total of five patents to his name, he has made significant contributions to the fields of chemistry and pharmaceuticals. His innovative spirit has driven him to explore and create novel solutions in the industry.
Latest Patents
Among his latest inventions, Landgraf has patented modifications of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminobenzene. Additionally, he has developed a novel modification of alpha-lipoic acid, which is related to thioctic acid characterized by a predominant amount of a specific enantiomer. Notably, the X-ray powder diffractograms of this invention demonstrate a characteristic reflex in the range of 23.4 to 22.7 degrees 2 theta (Cu), shifting towards smaller angular values as the enantiomer content increases.
Career Highlights
Throughout his career, Karl-Friedrich Landgraf has been associated with notable companies in the pharmaceutical sector, including Asta Medica Aktiengesellschaft and Arzneimittelwerk Dresden GmbH. His work at these organizations has been pivotal in the advancement of various medical solutions.
Collaborations
Landgraf has collaborated with respected colleagues, including Matthias Rischer and Alfred Olbrich. Together, they have contributed to the innovative landscape in their respective fields, fostering a creative environment that encourages invention and improvement.
Conclusion
Karl-Friedrich Landgraf's impressive portfolio of patents and his work with influential companies highlight his importance as an inventor in the modern landscape. His latest innovations showcase his dedication to advancing pharmaceutical science, and his collaborations with esteemed colleagues further emphasize the impactful contributions he continues to make.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile